Oct 25, 2013

Cardiovascular disease: the other face of diabetes

CPT: Pharmacometrics & Systems Pharmacology
G Vlasakakis, O Della Pasqua

Abstract

Despite glycemic control, evidence suggests that mortality and morbidity remain high in diabetes. Regulatory agencies deem, therefore, additional safety trials necessary for the approval of new antidiabetic drugs. Nevertheless, markers of cardiovascular risk, which can be used as response predictors, are not available. In contrast with current efforts on further understanding of glucose-insulin homeostasis, a model-based approach is required to assess the correlation between hyperglycemia and cardiometabolic phenotypes, enabling prediction of the underlying cardiovascular risk.CPT: Pharmacometrics & Systems Pharmacology (2013) 2, e81; doi:10.1038/psp.2013.57; advance online publication 23 October 2013.

Mentioned in this Paper

Hyperglycemia
Morbidity Aspects
Cardiovascular Diseases
Antidiabetics

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.